Duchem Bio Sees 47% Rise in Operating Profit... Net Profit Declines
"Expanding Sales of Alzheimer's Treatments"
Duchem Bio, a company specializing in radiopharmaceuticals, announced on the 29th that it recorded sales of 38.5 billion won and operating profit of 7.4 billion won in 2025. Last year’s sales increased by 8% compared to the previous year, while operating profit rose by 47%. Net profit for the period was 6.3 billion won, a decrease from 8 billion won in the previous year.
The company stated that the increase in diagnostic product sales following the introduction of an Alzheimer's treatment was a key factor behind these results. It explained that, starting from December 2024, sales of diagnostic products 'Vizamil' and 'Neuracheck', which are linked to prescriptions for Alzheimer's treatments, contributed to the rise in both sales and operating profit.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Kim Sangwoo, CEO of Duchem Bio, said, "Based on our diagnostic product business, we plan to expand into the field of therapeutic radiopharmaceuticals in the future."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.